Atlas Trials

Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen

Clinical trial NCT06680050 · RECRUITING

Trial details

NCT number
NCT06680050
Sponsor
Mario Negri Institute for Pharmacological Research
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Non Small Cell Lung Cancer NSCLC
Start date
2025-08-07
Primary completion
2028-06-01
Enrollment
21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.